Ms. Kristina Hachey reports

THERALASE(R) GRANTS STOCK OPTIONS

Theralase Technologies Inc. has granted stock options.

The company has granted an aggregate of 360,000 stock options to certain directors and employees pursuant to the company's stock option plan. The options granted, are exercisable at a price of 25 cents per share that vest over a three-year period and expire five years from the date of the grant. The stock option plan was last approved by the shareholders of the company at the annual general and special meeting of shareholders held on June 29, 2023.

About Theralase Technologies Inc.

Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.

We seek Safe Harbor.